Perceptive Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Perceptive Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500,000	Closed	-$38.5M	–	103
2024 Q4	$38.5M	Buy	+500,000	New	+$36.2M	1.06%	29

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Perceptive Advisors's PRAX Position: Q2 2026 in Review

Perceptive Advisors held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 2,035,986 shares worth $682M. The position accounts for 10.23% of the portfolio, ranked #1.

Perceptive Advisors first reported a position in PRAX in Q1 2024 and has held it in 10 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Perceptive Advisors held 2,035,986 shares of Praxis Precision Medicines worth $682M as of Q2 2026.
Perceptive Advisors left its Praxis Precision Medicines share count unchanged in Q2 2026.
Praxis Precision Medicines made up 10.23% of Perceptive Advisors's portfolio in Q2 2026, its #1 holding.
Perceptive Advisors first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 10 quarters since.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.